Utility of the Platelet-to-Lymphocyte Ratio in Diagnosing and Predicting Treatment Success in Preterm Neonates with Patent Ductus Arteriosus

Fetal Pediatr Pathol. 2021 Apr;40(2):103-112. doi: 10.1080/15513815.2019.1686786. Epub 2019 Nov 9.

Abstract

Background: We investigated the predictive ability of the platelet-to-lymphocyte ratio (PLR) in preterm infants to discriminate those with and without hemodynamically significant PDA (hsPDA and non-hsPDA), hsPDA defined by those requiring medical intervention.

Methods: This observational retrospective cohort study included premature neonates (<34 weeks gestational age) with routine complete blood counts in a neonatal intensive care unit.

Results: PLR values on the 1st, 2nd, 3rd, and 7th days of birth were higher and lymphocyte counts were lower in the hsPDA than in the non-hsPDA group. Plateletcrit (PCT) values on the 2nd and 3rd days of birth were lower in the hsPDA group. All hsPDAs closed with medical therapy.

Conclusions: PLR may be a supportive tool for predicting those preterm infants with PDAs requiring medical intervention. This may serve as a guide for future studies investigating the predictive value of PCT and PLR for hsPDA in preterm infants.

Keywords: Platelet; inflammation; lymphocyte; patent ductus arteriosus.

MeSH terms

  • Ductus Arteriosus, Patent* / diagnosis
  • Ductus Arteriosus, Patent* / therapy
  • Gestational Age
  • Humans
  • Infant
  • Infant, Newborn
  • Infant, Premature
  • Lymphocytes
  • Retrospective Studies